Universe Pharmaceuticals (NASDAQ:UPC) Trading 15.8% Higher – Here’s What Happened

Universe Pharmaceuticals INC (NASDAQ:UPC) shot up 15.8% on Thursday . The company traded as high as $3.16 and last traded at $3.16. 9,287 shares changed hands during mid-day trading, an increase of 80% from the average session volume of 5,156 shares. The stock had previously closed at $2.73.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Universe Pharmaceuticals in a research report on Tuesday, February 3rd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Universe Pharmaceuticals currently has a consensus rating of “Sell”.

Universe Pharmaceuticals Stock Up 15.8%

The business has a fifty day moving average of $3.08 and a 200 day moving average of $3.93.

Universe Pharmaceuticals (NASDAQ:UPC) last posted its earnings results on Thursday, January 29th. The company reported $0.69 earnings per share (EPS) for the quarter. The business had revenue of $8.92 billion during the quarter.

Universe Pharmaceuticals Company Profile

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.